Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 19/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.75 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.75 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.75 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.75 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12997598 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2B6CYP3A5 | |
| SCHEMBL1553787 | 0.86 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2B6CYP3A5 | |
| Voriconazole SCHEMBL28655272 | 0.86 | CYP3A4 (0.96) | CYP3A4CYP2C9CYP2C19CYP2B6CYP3A5 | |
| Voriconazole SCHEMBL29449336 | 0.86 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2B6CYP3A5 | |
| Voriconazole SCHEMBL824156 | 0.86 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2B6CYP3A5 | |
| Voriconazole SCHEMBL4709722 | 0.86 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2B6CYP3A5 | |
| Voriconazole SCHEMBL29449338 | 0.86 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2B6CYP3A5 | |
| Voriconazole SCHEMBL371715 | 0.86 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2B6CYP3A5 | |
| Voriconazole SCHEMBL1554444 | 0.86 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2B6CYP3A5 | |
| Voriconazole SCHEMBL3949267 | 0.86 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2B6CYP3A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680270-B2 | Metallo-oxidoreductase inhibitors using metal binding moieties in combination with targeting moieties | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| EP-2086546-B1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS INC (US) | 2013-07-10 | — | — | EP | disclosed |
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| EP-2086546-A2 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | Viamet Pharmaceuticals, Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008064311-A2 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | NQO1, SOD1, MDH2 | CYP3A4 1878/4885CYP2C9 2922/4885CYP2C19 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.